| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Common Stock | Options Exercise | $194,319 | +8,100 | +9.5% | $23.99 | 93,349 | 30 Aug 2023 | Direct | |
| transaction | SUPN | Common Stock | Sale | $259,200 | -8,100 | -8.7% | $32.00 | 85,249 | 30 Aug 2023 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | SUPN | Employee Stock Option (Right to Buy) | Options Exercise | $0 | -8,100 | -37% | $0.000000 | 13,900 | 30 Aug 2023 | Common Stock | 8,100 | $23.99 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.01, inclusive. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
| F2 | The option vests in four equal annual installments beginning on February 21, 2021. |